Vulnerability of Antioxidant Drug Therapies on Targeting the Nrf2-Trp53-Jdp2 Axis in Controlling Tumorigenesis
Cells · 2024
DOI: 10.3390/cells13191648 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Ying-Chu Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Antioxidants, Proto-Oncogene Mas, Carcinogenesis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, National Health Research Institute, Kaohsiung Medical University Chung-Ho Memorial Hospital.
Abstract (Originalsprache)
Control of oxidation/antioxidation homeostasis is important for cellular protective functions, and disruption of the antioxidation balance by exogenous and endogenous ligands can lead to profound pathological consequences of cancerous commitment within cells. Although cancers are sensitive to antioxidation drugs, these drugs are sometimes associated with problems including tumor resistance or dose-limiting toxicity in host animals and patients. These problems are often caused by the imbalance between the levels of oxidative stress-induced reactive oxygen species (ROS) and the redox efficacy of antioxidants. Increased ROS levels, because of abnormal function, including metabolic abnormality and signaling aberrations, can promote tumorigenesis and the progression of malignancy, which are generated by genome mutations and activation of proto-oncogene signaling. This hypothesis is supported by various experiments showing that the balance of oxidative stress and redox control is important for cancer therapy. Although many antioxidant drugs exhibit therapeutic potential, there is a heterogeneity of antioxidation functions, including cell growth, cell survival, invasion abilities, and tumor formation, as well as the expression of marker genes including tumor suppressor proteins, cell cycle regulators, nuclear factor erythroid 2-related factor 2, and Jun dimerization protein 2; their effectiveness in cancer remains unproven. Here, we summarize the rationale for the use of antioxidative drugs in preclinical and clinical antioxidant therapy of cancer, and recent advances in this area using cancer cells and their organoids, including the targeting of ROS homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
- Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
- Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
- Cell Therapy and Research Center, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.
- Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.
ORCID-Profile: Chia-Chen Ku, Kenly Wuputra, Kazunari K Yokoyama
Förderung
- Ministry of Science and Technology
- National Health Research Institute
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Kaohsiung Medical University
- National Health Research Institutes
- Kaohsiung Medical University Hospital
- National Sun-Yat-sen University-Kaohsiung Medical University Joint Research Project
Zitieren
APA
Lin, Y. C., Ku, C. C., Wuputra, K., Wu, D. C., & Yokoyama, K. K. (2024). Vulnerability of Antioxidant Drug Therapies on Targeting the Nrf2-Trp53-Jdp2 Axis in Controlling Tumorigenesis. Cells. https://doi.org/10.3390/cells13191648
Vancouver
Lin YC, Ku CC, Wuputra K, Wu DC, Yokoyama KK. Vulnerability of Antioxidant Drug Therapies on Targeting the Nrf2-Trp53-Jdp2 Axis in Controlling Tumorigenesis. Cells. 2024. doi:10.3390/cells13191648
BibTeX
@article{Lin2024,
author = {Lin, Ying-Chu and Ku, Chia-Chen and Wuputra, Kenly and Wu, Deng-Chyang and Yokoyama, Kazunari K},
title = {Vulnerability of Antioxidant Drug Therapies on Targeting the Nrf2-Trp53-Jdp2 Axis in Controlling Tumorigenesis},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13191648}
}
EUVIMED